OCKHAM CRO SOFTWARE
OCKHAM CRO TRIAL
OCKHAM CRO SERIES

OCKHAM CRO SERIES

This top-tier CRO posted revenues of $1.57 billion in 2015 – an impressive 4.8% increase over 2014 - and has completed a series of acquisitions in recent years, including MediMedia Pharma Solutions and Aptiv Solutions.

PRA experienced 8% growth in 2015, leading to over $1.4billion in revenues.

The company is also working to enhance vaccine research, and is pursuing additional capacity in biotech and bioanalytics.

OCKHAM CRO TRIAL

However, PRA is also completing a US-based project that is expected to add over 250 clinical trial assistant and clinical research jobs in the next few years, and has partnered with a UK-based marketing firm to increase recruitment of patients for its research across the globe. PRA’s drive toward international markets has grown since the company went public in 2014, with a specific focus on Singapore and other regional sectors. PPD reported revenues of over $1.35 billion for 2014, and continued growth in 2015.

OCKHAM CRO SOFTWARE

The company is also expanding its Preclarus data analytics software to further enhance clinical trial processes. Sales rumours aside, PPD is keeping busy, having recently signed a deal with biotech company Moderna to provide clinical trial support and coordination, and securing two US government contracts in late 2015 to support battlefield medicine innovations and evaluate influenxa vaccines. Pharmaceutical Product Development (PPD) recently split from its 2014 biotech acquisition, X-Chem, spurring market rumours that the privately-held PPD is up for sale or initial public offering (IPO). The company drew over $1.3billion in revenues in 2014, experienced substantial growth in 2015, and reports over 8700 employees in 17 countries. Charles River’s acquisitions expand its capacity in a variety of sectors and industries, diversify its customer base, and increase its reach within the global marketplace. This CRO’s acquisition spree has included Celsis International, the developer of rapid bacterial detection systems, preclinical cancer CRO Oncotest, and most recently WIL research, a provider of safety assessment services to pharmaceutical and agricultural companies.

The mid-sized organisation has grown to over 4000 employees across 47 countries with annual revenues approaching $1 billion. The company is a four-time winner of the CRO Leadership award by Life Science Leader magazine, and was identified as a top 10 clinical data management solution provider in 2015. Chiltern acquired Ockham, a cancer-focussed CRO, in 2014, and Theorem, a CRO with international reach and a strong clinical analytics programme. The company plans to enhance its research and development operations in the coming year, and expects to cross the $1 billion revenue threshold by the year’s end.Ĭhiltern’s global operations focus on three specialised sectors: Biopharma, Oncology, and Source, which offers functional service provider support including identifying staff and resources to meet clients’ individual demands. The company held a $150 million initial public offering in 2014, and saw a massive surge in sales that drove the company’s 14.2% increase over 2014 revenues, and solidified its status as a CRO to watch in 2016. INC Research earned the bulk of its $915 million in 2015 revenue through late-stage clinical trials, and, the same year, was given the Best CRO award by Scrip Intelligence and ranked Top CRO to Work With in the CenterWatch Global Investigative Site Relationship Survey. ProClinical published on 07/03/16 the following degressive ranking in its blog:

Ockham cro